Signaling Pathways in Endometrial Cancer Cells
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: 20 January 2025 | Viewed by 75
Special Issue Editor
Special Issue Information
Dear Colleagues,
Endometrial cancer (EC) develops from the uterine endometrial epithelium. Recent reports indicate that oncogenic mutations are already present in normal endometrium, suggesting that altered signaling pathways are involved in carcinogenesis. The PI3K/AKT/mTOR pathway is the most frequent activated signaling pathway in EC cells. This pathway governs cell proliferation, metabolism, and DNA damage repair. The RAS/MAPK pathway is also important for EC cell growth. However, inhibitors for both signaling pathways have not been successful in clinical trials. Historically, EC has been classified into two types according to hormone dependence. ER, PgR-positive, hormone-dependent ECs are sensitive to progesterone and aromatase inhibitors that partially block both the PI3K/AKT/mTOR and RAS/MAPK pathways. Recently, four molecular classifications have been proposed according to the TCGA project. POLE ultramutated and MSI subtypes are susceptible to immune checkpoint inhibitors. In contrast, the other two subtypes are resistant to immunotherapy. Interestingly, CDK4/6 and Wee1 inhibitors are effective for CN-L and CN-H subtypes, respectively. These findings indicate that modification of various signaling pathways may be useful in the treatment of EC.
Under this perspective, this Special Issue aims to describe the current advances in basic and translational research that focus on “Signaling Pathways in Endometrial Cancer Cells”.
Dr. Tomohiko Fukuda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- cellular signaling
- cell metabolism
- DNA damage repair pathway
- the PI3K/AKT/mTOR pathway
- the RAS/MAPK pathway
- molecular classification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
